2006 A phase III multicenter trial comparing two different sequences of second/third line therapy (cetuximab/irinotecan followed by FOLFOX versus FOLFOX followed by cetuximab/irinotecan) in metastatic K-RAS wt colorectal cancer (mCC) patients, refractory to FOLFIRI/Bevacizumab). Issue 3 (September 2015) - Cascinu, S.; Lonardi, S.; Rosati, G.; Nasti, G.; Zaniboni, A.; Romiti, A.; Aglietta, M.; Bilancia, D.; Iaffaioli, V.; Zagonel, V.; Giordano, M.; Corsi, D.; et al.